early a goals with and XX% the January, million in end, gross revenue full and $XXX I to the revenue to To we good Randy on saying today. call solid meeting all year for to those of $XXX underway, ourselves. guidance year set you, thank is out you margin to can focused morning our Thank XXXX offered ENT off XX%. objectives that we’ve Intersect feel start XXXX confident confirm joining well that the year I full in and With and a million fully between and of
it XXXX focus wish XXXX me the the confidence we on might we my XXXX. earnings part accomplished and much about enter as call, as However, to is continue why will XXXX I QX of to latter what gives in comments I this as as talk
great company. I than when The I and elected to excited ENT’s was am the ENT, state Intersect reputation First, Intersect about an months And portfolio I positive a join and have getting I most ENT. the outstanding me working among to the truly benefit attractive now, last large had evidence have current attracted and remain that as more significant elements the an all growth today. to of Intersect summer novel and solidly pipeline. over innovative We last let physicians of company, me the clinical technology, criteria of teams of talented board openly that committed prospects today engage potential the as well products closely these at here each X and terrific talent know and of with market,
As and presentations XXXX draw. you, strengths is there we to in have to But foundational which I to must we realize our work still are do many said look full potential. as there calls from many in with beyond and of recent
PROPEL is that while With to that backdrop, and necessary, past differentiated and clinically SINUVA to is most best-in-class level compelling. strategies it as evidence that from notion clinical seek. insufficient the are plans months X the informs and this perhaps simple striking is unto growth the we drive insight itself our technologically
products where offer However, developed We the selling Clinical in drive to examples evidence physicians, and penetration and sustained is itself must we strong best practices. adoption, deep evidence to full use double-digit clinical is crucial. their and not also evidence by how of market sufficient growth. consistently compelling our
it infrastructure perhaps efforts selling clinical the and actions strong access back of our that and you products access targeted with makes the that of more into to evidence, importantly, need as and easy they market access XXXX in appropriate and our half ensure XXXX. guided via our informs addition institutions might to wish. In products physicians and The for market payer need simple ensured procure insight reimbursement unencumbered combination our going use we to
be and solutions both development end, for of To we our commercial our SINUVA basics needs The at physician our physician of obstacles identify can in coverage we focusing and the sales to individual market will began capture we field more currently and how to systematically recommendations, a and to for to in intentional products efforts allow effort back individual basics the physician continue individual chronic enabling granular prioritized tailor that and physician have rhinosinusitis. and better that We they start forward. that us These clinical clear more and time. by started doctor nature level our insights and treating as specific go of over with execution XXXX novel the on rigorous understand PROPEL universe selling XXXX moved reimbursement segmentation additional payer level to level. use coverage to use data products
very clear, is and of organization be To Intersect sales the our deep talented ENT has markets. the understanding
physicians opportunity commercial in strong But believe the an we truly data may deeper and physician have We to serve. drive game. grow and in and and the our and practice penetration well-established relationships and XXXX the The execution with beyond to also institutions we differentiated growth. payer field rekindle I enjoy up to drive insight strong our use and enhanced knowledge of greater relationships will expand
roles, XXXX, performance. sales rewards that tied direction in further to will commercial addition and we In refine the
both the medical a a challenged as to With use delivering combination The product in time offices, PROPEL, in the a we at ASC SINUVA, same support drug for pulled multiple SINUVA. of was were regulated the sales with organization launch the directions. while device hospital in
ENT learning, requirements our of XXXX. drug frankly, in do in therapy we SINUVA. with have to With infrastructure necessary quite and not offices of addition, we In this support changes important place spite initiating previously in adequate the best made efforts, in
on selling focus in of sufficiently improved with PROPEL our In and appropriately sales late proportionately models addition and that SINUVA. the we ensure XXXX to the to we of launch franchise, market aligned half did and driving development, clinical analytical XXXX force and in we reward insight, were something our not front
the to our further to time, doing of and penetration of sales redeployed our focused so, infrastructure. core engaging while in third-party access to our drive rewards we bulk all aligned expanded At best team business. PROPEL now clinical our needed specialists address The around much effort the growth force executing SINUVA, needs SINUVA is in appropriate are of talent return incentive majority PROPEL surgical additional of specific and procedures. for unique same core to the strategy to In selling sales on market the and the provide and
the while we additional also payers. of in for SAMs, strategic teams support on we office reimbursement ENT reimbursement story of supporting in XX QX local Specifically, ENT directors, per the added setting. clinical managers, account to the with last Two, RRDs, selling with access SINUVA to and XX staff maximizing in charged it office. SINUVA the on field appropriate office regional national and Intersect this month interfacing XX our And an at reimbursement in coordinated, focused, mirrored and and deployed employee also region clinical and sales trained focus guidance the procedure processing SINUVA one ease structure sales finalized We to meeting. seeking training
the hub to October, went patient coverage of a new SINUVA. determining insurance extent ENT support and staff also in we for In with nature patient office physician live
complement existing also our capabilities. We on brought pharmacy specialty board to a new
process manage in insurance to benefit as of used for adjudication new selected go was specialty seamless in their both payers our support payer to and our designation, by partner December. augmented thereby take Likewise, of by SINUVA. more pharmacy and medical designation distributor product. SINUVA access adding ability can our Our physicians believe Regardless benefit through covering capability McKesson specifically they providing we we the delivery now office better a we
and now for with J alike. J specific our the payers. a published XX% therapy landscape initiating our benefit No The QX there in streamline and reimbursement code Commercial lot and reimbursement and the and of J physicians code around office. of with and a made of experience receive Medicaid code utilization a while the live see of to the for we under the we we the payment especially using last Finally, CMS to to increasingly field teams. the commercial our we yet have furthered code, their and for have also doubt went complexity J have serve much in payers disappointed patients clearer navigating adoption remain Medicare. rate we SINUVA reimbursement the year created in of path learnings covered role the and clarity But to simplifying physicians we are is investment drug population greater new from we new substantially was that
to efforts renewed a have Reflecting as ENT product proud on return demands approach XXXX, I With Intersect in preparing drug our have brand we our and the a adopted of are more team’s our the the With of therapy foundational force the company. to accomplishments with PROPEL, on proportionate in of for growth importance sales of was in XXXX. am office. PROPEL that the go-to-market initiating SINUVA, more consistent the we
specialist do have capability alleviate the clear, past assistance be provide by a to SINUVA of and not the establishing point. sales finely-tuned distraction and customers. have to clinical office-based We at the To teams aligned force to SINUVA we reimbursement specific machine this our
and To the our are in each great SINUVA we growth of enhanced objectives that we we of in end, noted, getting and of both and PROPEL the market go-to-market are committed are are invested out infrastructure XXXX. strides access in you clinical made Bottom this execution XXXX the the have of As and SINUVA half built one the front have as for still well accelerated half foundation overall our back over meaningful year. refining penetration reflecting have for the as upon SINUVA the growth utility further laid but in gears, investor sand XXXX. market commercial confident to asset and we line, model
sustained view, presented to claims, of the briefly our my substantial product the like important R&D, The we substantial deliver ASC excellent delivery the an innovation our the organic, to line the innovation, I a moderate delivering innovation compliment SINUVA in It’s our opportunity claims of drive let’s steady and area from and procedure as platform pipeline. growth. conducted drug and term to offers in believe steadfastly it publications the drug-coated conference on the to and In of incremental a across this see market. and and of office. in platforms bullish extensions remained is cadence a more importance platforms. product continuum future PROPEL In and posters. SINUVA there balloon sinus Now, new balloon longer to new news new look growth by to consistently and drug-coated PROPEL and continuum localized in hospital, to drive
Intersect balloon. ability PMA demonstrated and trial clinical FDA teams statistically forward. versus the conventional ASCEND significant week with reduction provide to greater and edema balloon regulatory ASCEND with next discuss to meeting steps inflammation drug-coated polypoid balloon appropriate and drug-coated this the our ENT’s are Our our to a bring in requirements
We when will bullish. those appropriate but and available, we learnings share as are
We longer delivery cases. in development innovation and in drug work high We the different also human discussed XXXX, at animal allow that should level this funded used a trials January very in publicly on format for studies promise XXXX XXXX that a offers further in the fully localized platform more of initiate sinus completed future. are in to albeit in early a us acting for
but needs Beyond larger extensions respective was variance post-surgical Both balloon, Mini an in a address product and with able PROPEL product for drug-coated to the SINUVA platform lend expanding is play to their core important Contour. PROPEL, our range of ENT lines. line broader themselves the Intersect and complementary, role further offerings of technologies. of PROPEL platform innovation, distinct there to
the of enhancing additional to internal in work economic funnel offers provide evidence. our health innovation broader an inform clinical as this to our well Product expect evidence coming utility innovation claims We years. avenue as
front focus can product intentional claims supplemented and with innovation acquisitions. and determined further road be our down Lastly, complimentary on the tuck-in appropriate and organic
is designed ensure some incremental growth. sustainable together, of and more provide a substantial some Taken long-term this to drive innovation, and to strategy steady cadence
innovation, is to of to believe well-positioned access integrated I innovative the and levers to execution, ENT of continued player from comprehensive technology transition and time With an dual the with more enhanced over coupled commitment company a scale. commercial company
need will and However, right as by consistently we commitments. on our executing earn with plan, that every aspect of this delivering to
XXXX. like a out call to I final Before to Randy, few would over close the I hand observations make to
believe First, that am I truly ENT bright. at excited to and be to as I have is mentioned, continue already Intersect future
culture be the our certainly is of there and we While for growth in foundation marketplace, of teams. commitment the and and the is the more present work done, have unmet reflected foundational to products the needs
development half second entire guidance, the how our in the proud commercial provided to efforts infrastructure organization together XXXX. PROPEL our came am market around as and revised primary really basis the in XXXX guidance. basics and both rallied with of revised XXXX our And teams initial our confidence back for Second, objectives to of access while these the we to us Achieving objective I XXXX. and growth SINUVA achieve a establish
for want Third, at XXXX. and business in last time importantly uniting Lisa, I thank and transition. demonstrated and lot The return And the has of decade. the service to the past our of a a our year. to year, perseverance. most built easy, the at assistance to end, the transition wanted role also one steadying engaging this I leadership entire meaningful with pivotal would day-to-day and This Throughout company confident the for of Chairman, into retirement leadership especially Kieran acknowledge I commitment the smooth together the Kieran and the all her growth technology played that organization I remain around And teams provide leadership organization a endured Jeri’s her year entire more into stepping thank the is behalf team. to start in to operations company, the grip to for at of never interim our thank a of the over ENT in and Gallahue guidance. Intersect to the a we board and and Executive his Overall, ensuring and testament the transitions provide to throughout series grateful. Jeri while thanks in we others year support future, personally transition that’s the guidance leadership in deeply like speaking future providing in outlook special for from am more a to on our
to to me you now Let Randy financial our call results over take our turn and the through outlook.
